The above article supports the value of low-level infrared light stimulation using sophisticated blood oxygenation and imaging technology. We used similar though less advanced tools in our 2012 study 28 days of 6-minute, transcranial and intraocular 1065-1075nm photobiomodulation of subjects struggling with probable Alzheimer's disease. The current study using the same device is now 56-days with more powerful lLED stimulation.
This recent article by my colleague Michael Hambin, PhD offers a well organized and rather complete review of the current state of the science related to the clinical application of low level light stimulation. The edited volume on the subject Photobiomodulation and the Brain has recently been published by Elsevier and contains a chapter on the integration of neurofeedback photobiomodulation by myself, Trent Nichols, MD and our colleagues Jason Huang MD and Damir Nizmutdiinov MD PhD from Baylor Scott & White Research Institute.
We are seeing terrific results within our clinic using these tools and are excited by the future applications that are being created based on this and other research.
Our approach to treatment is aligned with Dr. Perlmutter, Bredesen and supports the Institute for Functional Medicine's model for clinical intervention by boosting the capacity for recovery and healing. Photobiomodulation stimulates mitochondria to produce more ATP and thereby improve the brain's ability to function efficiently. Neurofeedback adds an important component to this process by improving the neural connectivity that allows for continued improvement by having renormalized brain network functioning. Functional medicine works to remove the underlying bacterial, viral and toxic contributors to neurophysiological deterioration.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.